ARTICLE | Clinical News
Humira adalimumab: Phase III data
August 25, 2008 7:00 AM UTC
In the double-blind, international Phase III DE038 trial, adalimumab met the primary endpoint of reducing the number of flares compared to placebo in 133 evaluable patients ages 4 to 17 years old who ...